DENV1 Polyprotein Specific Neutra™ Antibody Products

Are you grappling with the challenges of dengue virus serotype 1 (DENV1) research, such as cross-reactive assays, elusive epitope targeting, or inefficient neutralization? Creative Biolabs' DENV1 Polyprotein Specific Neutra™ Antibody Products empower your work with high-specificity, rigorously validated antibodies engineered through advanced phage display and epitope-focused design, enabling accurate detection, functional blockade, and accelerated therapeutic discovery.

Introduction to DENV1 Polyprotein

The Dengue virus serotype 1 genome polyprotein serves as a crucial precursor for viral infectivity and pathogenesis. After the virus enters host cells and undergoes translation, this single polypeptide is cleaved by both viral and host proteases into three structural proteins (Capsid C, prM/M, and Envelope E) and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5). This polyprotein regulates the viral lifecycle, including particle assembly and immune evasion. While it remains highly conserved within serotype 1, substantial variability exists among serotypes 1-4, impacting serotype-specific immunity and hindering broad-spectrum therapeutic approaches.

• Structural Insights

Cryo-EM and X-ray crystallography studies have resolved critical domains within the polyprotein, particularly the E protein domain III (EDIII), which is a major target for potent, type-specific neutralizing antibodies. The conformational dynamics of the prM-E heterodimer during viral maturation are crucial for understanding antibody-mediated neutralization.

Fig.1 Arrangement of the DENV polyprotein and the expression constructs employed in this study (protein region sizes are not to scale).¹

• Resistance and Signaling Pathways

DENV1 polyprotein cleavage products, notably NS1, NS3, and NS5, actively interfere with host innate immune signaling pathways, including the type I interferon (IFN-α/β) response and the RIG-I/MDA5 pathway. NS5 also modulates STAT2 degradation, effectively suppressing IFN-stimulated gene expression and facilitating viral replication.

• Clinical Impact

DENV1 infection can lead to a spectrum of diseases, from self-limiting dengue fever to severe, life-threatening dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). The risk of severe disease is heightened by antibody-dependent enhancement (ADE), where sub-neutralizing or cross-reactive antibodies from a prior infection can exacerbate a subsequent heterotypic infection.

• Antibodies Against DENV1 Polyprotein Peptide
  Neutralizing antibodies targeting specific epitopes on the DENV1 polyprotein, particularly within the E and prM proteins, are critical tools for research and therapeutic candidates. They enable:
  • Precise serotyping and viral load quantification.
  • Functional studies of viral entry and assembly.
  • Assessment of neutralization potency while minimizing ADE risk.
  • Development of serotype-specific vaccines and therapeutics.

Applications of Anti-DENV1 Polyprotein Neutralizing Antibodies

Fig.2 Mechanism of anti-DENV1 neutralized antibody-mediated neutralization of DENV1 in cell lines.²

• Serotype-Specific Diagnostic Assay Development

Our high-affinity anti-DENV1 polyprotein antibodies are instrumental in developing rapid, serotype-specific immunodiagnostic tests. By targeting unique conformational epitopes on the DENV1 E protein, these antibodies eliminate cross-reactivity with other DENV serotypes or related flaviviruses like Zika. This specificity is crucial for accurate patient management, epidemiological surveillance, and understanding disease dynamics in co-circulation areas, enabling timely and appropriate clinical interventions.

• Vaccine Efficacy and Immune Response Profiling

Evaluating the quality and durability of vaccine-induced immunity requires precise tools. Our Neutra™ antibodies serve as critical reagents in plaque reduction neutralization tests (PRNT) and microneutralization assays to quantify serotype-specific neutralizing antibody titers in vaccinated individuals or convalescent patients. This application is vital for determining correlates of protection, assessing vaccine candidate efficacy, and monitoring potential waning immunity over time.

• Therapeutic Candidate Screening and Mechanism Study

Our antibodies provide a gold standard for screening and characterizing novel therapeutic candidates, such as small molecules or other biologics aimed at inhibiting viral entry. In in vitro models, they are used in competitive binding assays to map inhibitory mechanisms. Furthermore, they are invaluable for studying the structural basis of neutralization and the risk of ADE, guiding the development of safer, next-generation antiviral therapies.

Our Anti-DENV1 Polyprotein Neutralizing Antibodies

Creative Biolabs delivers premium antibody solutions designed for the most demanding dengue research:

High Specificity and Low Cross-Reactivity: Meticulously validated to ensure exclusive binding to DENV1 epitopes, minimizing interference from other DENV serotypes or flaviviruses.

Potent Neutralizing Activity: Functional validation in a standardized cell-based assay confirms robust neutralization capability.

Epitope-Defined Reagents: Antibodies are characterized for binding to key domains, providing tools for mechanistic and structural studies.

Rigorous Validation: Consistently performance-tested across multiple applications, including ELISA, Western Blot, Immunofluorescence, and neutralization assays.

Customizable Formats: Available in various conjugates and sizes to seamlessly integrate into your established workflow.

Creative Biolabs is your trusted partner in infectious disease research. We combine deep scientific expertise with a commitment to delivering reproducible, high-performance reagents. Our DENV1 Polyprotein Specific Neutra™ Antibody Products are more than just reagents; they are precision tools engineered to accelerate your path from discovery to development. Contact our scientific team today to discuss your specific project requirements and request detailed product specifications.

References

1. Ponndorf, Daniel, et al. "Plant‐made dengue virus‐like particles produced by co‐expression of structural and non‐structural proteins induce a humoral immune response in mice." Plant Biotechnology Journal 19.4 (2021): 745-756. Distributed under Open Access license CC BY 4.0, without modification. Doi: https://doi.org/10.1111/pbi.13501
2. Fibriansah, Guntur, et al. "A potent anti‐dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface." EMBO molecular medicine 6.3 (2014): 358-371. Distributed under Open Access license CC BY 4.0, without modification. Doi: https://doi.org/10.1002/emmm.201303404